Atrys Health (XMAD:ATRY) Momentum Rank: 4 (As of Aug. 23, 2026) — 33% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:ATRY Atrys Health SA XMAD:ATRY
62 GF Score
Price €2.53
GF Value €3.22
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Atrys Health Momentum Rank?

Atrys Health XMAD:ATRY -0.78% 62 Momentum Rank is 4 as of Aug. 23, 2026, which is 33% above its 10-year median of 3.00. GuruFocus rates XMAD:ATRY with a GF Score™ of 62/100 and a GF Value™ of €3.22 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Atrys Health has the Momentum Rank of 4.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Atrys Health Momentum Rank Related Terms

XMAD:ATRY vs VRTX, REGN, RVMD: Momentum Rank Comparison

For the Biotechnology subindustry, Atrys Health's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrys Health Momentum Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrys Health's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Atrys Health's Momentum Rank falls into.


XMAD:ATRY
62GF Score
Atrys Health SA XMAD:ATRY
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 4 mean?
Atrys Health (XMAD:ATRY) has a Momentum Rank of 4 as of Aug. 23, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Atrys Health and its competitors. This is 33% above median its historical median of 3.00. Over the past decade, Atrys Health's Momentum Rank has ranged from 1.00 to 9.00.
Is Atrys Health's Momentum Rank too high?
Atrys Health's current Momentum Rank of 4 is 33% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. Overall, Atrys Health has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's Momentum Rank compare to VRTX and REGN?
Atrys Health's Momentum Rank of 4 can be compared against companies in the Biotechnology industry. Historically, Atrys Health's own Momentum Rank has ranged from 1.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Biotechnology company?
A good Momentum Rank depends on the Biotechnology industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Atrys Health and its competitors. Atrys Health's current Momentum Rank is 4, which is 33% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.22, compared to a current price of €2.53 — trading 21.4% below its estimated fair value. The current Momentum Rank is 4, which is 33% above median its 10-year median of 3.00. Atrys Health's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current Momentum Rank is 4 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.53 is trading 21.4% below its estimated GF Value™ of €3.22. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

  • Momentum Rank: 4 (33% above median its 10-year median of 3.00)
  • GF Value™: €3.22 vs. price of €2.53 (21.4% below fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atrys Health Business Description

Other Exchanges A2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
62GF Score

Get the complete analysis for XMAD:ATRY

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.53
Price
€3.22
GF Value